摘要
目的:评价罗补甫克比日丸治疗弱精子症的经济性。方法:基于已发表的罗补甫克比日丸治疗弱精子症的随机对照试验研究,对罗补甫克比日丸治疗弱精子症进行成本-效果分析。结果:患者用药后,罗补甫克比日丸治疗方案在改善精子前向运动百分率和总有效率方面高于维生素E软胶囊治疗方案。以维生素E软胶囊为参照,针对治疗前后精子前向运动百分率差值,计算罗补甫克比日丸的增量成本-效果比(ICER)为11 452.30,同时达到临床意义界值需多花费3 664.74元,约为2021年我国人均可支配收入(PCDI,35 128.00元)的10.43%;针对治疗后总有效率,计算罗补甫克比日丸的ICER为4 094.10,约为2021年我国PCDI的11.65%。结论:本研究认为,基于2021年我国PCDI作为患者支付意愿阈值的假设,在改善弱精子症患者治疗前后精子前向运动百分率差值、提升临床总有效率方面,使用罗补甫克比日丸比使用维生素E软胶囊更具有经济性。开展罗补甫克比日丸治疗弱精子症的经济学评价,有助于提高医药资源配置的总体效率。
OBJECTIVE:To evaluate the economical efficiency of Luobufukebiri pills in the treatment of asthenospermia.METHODS:The cost-effectiveness of Luobufukebiri pills in the treatment of asthenospermia was analyzed based on the published randomized controlled trials of Luobufukebiri pills for the treatment of asthenospermia.RESULTS:After patient administration,the therapeutic regimen of Luobufukebiri pills was higher than the therapeutic regimen of Vitamin E soft capsules in terms of improving the percentage of forward sperm motility and total effective rate.Taking Vitamin E soft capsule as a reference,for the difference value in the percentage of forward sperm motility before and after,the incremental cost-effectiveness ratio(ICER)of Luobufukebiri pills was calculated to be 11452.30,and the additional cost to reach the clinical significance cut-off value was 3664.74 yuan,which is about 10.43%of China’s per capita disposable income(PCDI,35128.00 yuan)in 2021;for the total effective rate after treatment,the ICER of Luobufukebiri pills was calculated to be 4094.10,which is about 11.65%of PCDI in China in 2021.CONCLUSIONS:Based on the assumption of China’s PCDI in 2021 as the threshold of patients’willingness to pay,the application of Luobufukebiri pills has more economical efficiency than that of the Vitamin E soft capsules in improving the difference value in the percentage of forward sperm motility and promoting the clinical total effective rate.Carrying out the economic evaluation of Luobufukebiri pills in the treatment of asthenospermia contributes to improving the overall efficiency of medical resource allocation.
作者
魏仲义
崔鑫
谢雁鸣
WEI Zhongyi;CUI Xin;XIE Yanming(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China)
出处
《中国医院用药评价与分析》
2024年第2期222-226,231,共6页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
国家重点研发计划项目(No.2018YFC1707400)
国家中医药管理局2021岐黄学者支持项目(No.国家中医药人教函[2022]6)
谢雁鸣全国名老中医药专家传承工作室建设项目(No.国家中医药人教函[2022]75)。